Belgium· BE-AMP-SAM292704-00

Elaprase 2 mg/ml

A idursulfase product containing idursulfase, registered in Belgium by Takeda Pharmaceuticals International Ireland Branch. The same ATC class is registered in 14 of our 19 countries.

ATC A16AB09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedElaprase 2 mg/mlATCA16AB09REGISTER NO.BE-AMP-SAM292704-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Idursulfase is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB09 (idursulfase), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose

Idursulfase · ATC A16AB09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Idursulfase
Manufacturer
Takeda Pharmaceuticals International Ireland Branch
Country
Belgium (BE)
ATC code
A16AB09
ATC class
Idursulfase
Defined daily dose
5 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0787655
  • be_apb
    2476265

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/35351225-b5f8-4fd1-aae1-85b0b58e2dd2
GET /v1/drugs/35351225-b5f8-4fd1-aae1-85b0b58e2dd2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Elaprase 2 mg/ml",
  "name_fr": "Elaprase 2 mg/ml",
  "name_nl": "Elaprase 2 mg/ml",
  "amp_code": "SAM292704-00",
  "strengths": [
    "2.0000",
    "0.4820"
  ],
  "pack_count": 3,
  "substances": [
    "Idursulfase",
    "Sodium Phosphate Monobasic Monohydrate",
    "Polysorbate 20",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Idursulfase",
  "authorisation_numbers": [
    "EU/1/06/365/001",
    "EU/1/06/365/002",
    "EU/1/06/365/003"
  ]
}

See everything about idursulfase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.